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Introduction: Developmental dysplasia of the hip (DDH) is a common musculoskeletal disorder that has pain and
loss of joint function as major pathological features. In the present study, we explored the mechanisms of possible
involvement and regulation of substance P (SP) and calcitonin gene-related peptide (CGRP) in the pathological and
inflammatory processes of arthritis in DDH.
Methods: Blood, synovial tissue and fluid samples were collected from patients diagnosed with different severities
of DDH and from patients with femoral neck fracture. Levels of SP, CGRP and inflammatory cytokines in synovium
and synovial fluid (SF) in the different groups were evaluated by immunohistochemistry, real-time PCR and
enzyme-linked immunosorbent assay (ELISA). Correlations between neuropeptides and inflammatory cytokines in
SF were evaluated by partial correlation analysis. The proinflammatory effects of SP and CGRP on synoviocytes
obtained from patients with moderate DDH were investigated in vitro by real-time PCR and ELISA. The mechanisms
of those effects were evaluated by Western blot analysis and nuclear factor κ-light-chain-enhancer of activated B
cells (NF-κB) DNA binding assay.
Results: Significantly increased levels of neuropeptides and inflammatory cytokines were observed in synovium and
SF from patients in the severe DDH group compared with the moderate DDH and control groups. In moderate
DDH samples, SP in SF correlated with tumor necrosis factor (TNF)-α, and CGRP in SF correlated with TNF-α and
interleukin (IL)-10. In the severe DDH group, SP in SF correlated with interleukin (IL)-1β, TNF-α and IL-10. CGRP in SF
correlated with TNF-α. Additionally, SP might have had obvious proinflammatory effects on synoviocytes through
the activation of NF-κB.
Conclusions: The upregulation of SP and CGRP in synovium and SF might participate in the inflammatory process
of arthritis in DDH. The activation of the NF-κB pathway seems indispensable in the proinflammatory effect of
SP on synoviocytes. This original discovery may indicate a potential clinical drug target and the development of
innovative therapies for DDH.* Correspondence: chenxdmd@163.com
†Equal contributors
Department of Orthopaedic Surgery, Xinhua Hospital, Shanghai Jiaotong
University School of Medicine, No. 1665, Kongjiang Road, Yangpu District,
Shanghai 200092, People’s Republic of China
© 2015 Wang et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
Wang et al. Arthritis Research & Therapy  (2015) 17:4 Page 2 of 12Introduction
Developmental dysplasia of the hip (DDH), formerly
known as congenital dysplasia of the hip, affects 1% to
5% of babies in China, and the reported female-to-male
ratio ranges from 4:1 to 10:1 in different populations
[1,2]. Shallow acetabulum, slacking joint capsule, nar-
rowing joint space and disorder of the hip joint are the
main anatomic features of DDH, which result in chronic
pain, inflammation around the hip joint, synovial hyper-
plasia and hypertrophy in fossa acetabuli. Abnormal
shear load on the cartilage surface can also induce sec-
ondary osteoarthritis (OA) and cartilage degeneration. In
addition, a phenomenon frequently observed in young
adult patients in the clinic is moderate DDH (slight pain
and joint restriction) (Figure 1A) that leads to severe
DDH (acute pain, joint dysfunction and obvious OA)Figure 1 Radiographs and experimental data of patients with develop
developmental dysplasia of the hip (DDH) (A) and severe DDH (B). mRNA
(CGRP) (D) in synovial tissues obtained from patients in the study groups: m
*P < 0.05 versus control group. #P < 0.05 versus moderate DDH group. (E) t
inflammatory cytokines (interleukin (IL)-1β, tumor necrosis factor (TNF)-α an
*P < 0.05 versus moderate DDH. SF, Synovial fluid. Data represented are me(Figure 1B) within a few years. Undoubtedly, both of
these stages of DDH can sharply diminish the patient’s
quality of life.
Clinically, series of osteotomies have been widely im-
plemented for the treatment of DDH in young adults
[3]. However, little is known about the mechanisms of
pain and the pathogenesis of arthritis development in
DDH. In recent studies, researchers have observed syn-
ovial hyperplasia and hypertrophy in the acetabular
fossa, especially in weight-bearing areas of the hip joint,
in patients with OA [4,5]. Furthermore, sensory nerve fi-
bers in human labrum and synovium have been found to
be immunoreactive with protein gene product 9.5, calci-
tonin gene-related peptide (CGRP) and tumor necrosis
factor (TNF)-α in patients with hip pain or rheumatoid
arthritis (RA) [6], suggesting the possible involvementmental dysplasia of the hip. Radiographs depicting moderate
expression of substance P (SP) (C) and calcitonin gene-related peptide
oderate DDH (n = 10), severe DDH (n = 11) and control (n = 8).
hrough (I) Concentrations of neuropeptides (SP and CGRP) and
d IL-10) were detected by enzyme-linked immunosorbent assay.
an ± standard deviation.
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hip pain.
Inflammatory processes and associated activation of
the central and peripheral nervous systems are regarded
as the main reasons for the pain sensation in OA. Among
these reasons, tachykinin family members, such as sub-
stance P (SP) and CGRP, that participate in nociceptive
transmission and the proinflammatory process have been
proved to be widely involved in the progression of knee
and ankle joint arthritis [7,8]. In addition, inhibitors of
the ubiquitin–proteasome system, along with other
forms of pain-relieving therapies, have been found to be
able to restrain the progression of arthritis in rats by
specifically decreasing the expression of SP and CGRP
in synovium [9,10].
SP is a member of tachykinin family and is known to
be extensively involved in the neurogenic inflammatory
process [11]. Upregulated SP levels in synovium and syn-
ovial fluid (SF) have been observed in patients with RA
[12]. In addition, SP has been demonstrated to facilitate
vasodilatation and plasma extravasation into the synovial
cavity, which probably contributes to arthritis progression
[13]. The biological responses to SP are mediated by the
neurokinin-1 receptor, a G protein–coupled receptor for
SP bearing seven transmembrane domains, which have
been observed in lymphocytes, monocytes, macrophages
and rheumatoid synovial fibroblasts [14].
CGRP is a 37–amino acid neuropeptide that is released
primarily from sensory nerve fibers and is well known as
the most potent and longest-lasting microvascular vaso-
dilator in vitro and one of the most hypotensive agents
in vivo [15]. CGRP distributes throughout the central and
peripheral nervous systems and exhibits a range of bio-
logical effects on the mediation of inflammation and pain.
Owing to its potent cardiovascular effects, CGRP, together
with SP, is widely involved in the inflammatory pain syn-
drome of arthritis, as well as in other acute and chronic
diseases, such as thermal injury and periodontitis [16,17].
Proinflammatory cytokines also play a pivotal role in the
pathophysiological process of RA [18]. A close association
between the augmented level of inflammatory cytokines in
SF and functional degeneration of articular cartilage has
been observed in patients with RA [19,20]. Interleukin
(IL)-1β and TNF-α secreted by activated synoviocytes,
monocytes and macrophages were observed to induce cas-
cades of inflammatory events, including cartilage degrading
matrix metalloproteinase (MMP) expression, prostaglandin
E2 release and nitric oxygen production [21-24]. These cy-
tokines could act as a trigger, exacerbating the inflamma-
tory process and stimulating the release of chemokines.
The inflammatory cascade was observed to intensify as a
result, which in turn increased the destruction area [25].
Interactions between neuropeptides and cytokines in
RA and OA are well recognized. However, the researchto date regarding the mechanism of pain development
and the pathological progress of arthritis in DDH is lim-
ited. In addition, the relationship between neuropeptides
and proinflammatory cytokines in the synovium and SF of
patients with different stages of DDH remains unknown.
Therefore, the objective of this study was to explore the
possible proinflammatory properties of neuropeptides in
the synovium and SF of patients with DDH and to investi-
gate the role played by neuropeptides during the develop-
ment of DDH. We sought to improve the understanding
of the pathological process in DDH.
Methods
Patients and materials
This study was carried out in accordance with the Declar-
ation of Helsinki and was approved by the ethics commit-
tee of Xinhua Hospital affiliated to Shanghai Jiao Tong
University School of Medicine. Samples obtained from op-
erations were prepared only for testing purposes and with
the approval and signed consent of the patients.
The clinical data and samples included in this study
were obtained from patients who underwent surgical
treatment at our institution between March 2012 and
December 2013. Patients involved in this research were
divided into three groups according to their clinical diag-
nosis and disease severity. Thirty-five patients (mean age,
23.8 years; age range, 21 to 36 years) with DDH (Crowe
grades I and II) and OA (grade 0 or 1 on the Kellgren-
Lawrence (K-L) scale) were set as the moderate DDH
group. Thirty-two patients (mean age, 27.4 years; age
range, 26 to 46 years) with DDH (Crowe grade I or II) and
OA (grade 3 or 4 on the K-L scale) were set as the severe
DDH group. The degree of hip joint dislocation and sever-
ity of OA were divided according to the patients’ Crowe
and K-L grades, respectively, which were determined in
the clinic [26,27]. The reference group consisted of 15 pa-
tients (mean age, 30.4 years; age range, 25 to 38 years)
who underwent traumatic femoral head or neck fracture
but had no joint diseases noted in their previous medical
records [28-30].
The diagnosis of DDH was based on the standard of a
hip with a sharp angle <45° and a center edge angle <20°
[31,32]. Patients with moderate DDH underwent periace-
tabular osteotomy (PAO) or osteochondroplasty (OCP),
and those with severe DDH underwent total hip arthro-
plasty (THA). Patients in the control group underwent
emergency internal fixation or hemiarthroplasty within
24 hours after injury. The data compiled from clinical and
laboratory examinations of patients in all groups are listed
in Table 1.
The synovial tissues obtained during the operations
were immediately cut into 1-cm3 pieces and prepared for
three applications. (1) Some pieces were immerged into
RNAlater (catalog number AM7021; Ambion, Austin, TX,
Table 1 Clinical information of patients recruited into this
studya
Moderate DDH Severe DDH Control
Number of patients 35 32 15
Mean age (yr) 23.8 ± 6.5 27.4 ± 5.7 30.4 ± 3.5
Female/male (n) 28/7 22/10 9/6
BMI (kg/m2) 23.4 ± 2.1 24.8 ± 2.3 23.8 ± 1.9
Duration (yr) 2.7 5.5 –
CRP (mg/L) 11.79 ± 3.8 13.1 ± 4.6 10.9 ± 6.5
ESR (mm/1st hr) 16.2 ± 3.0 24.4 ± 4.5* 19.6 ± 4.7
Harris Hip Score 74.6 ± 9.9 62.8 ± 12.4* –
Visual analogue scale score 38.2 ± 13.2 57.8 ± 10.3* –
aBMI, Body mass index; CRP, C reactive protein; DDH, Developmental dysplasia
of the hip; ESR, Erythrocyte sedimentation rate. The Mann–Whitney U test was
applied for comparisons between groups. *P < 0.05 versus moderate DDH
group. Data are presented as mean ± standard deviation.
Table 2 Sequences of PCR primers related to
neuropeptides and inflammatory cytokines included
in this studya
Gene Forward primer (5′-3′) Reverse primer (5′-3′)















aCGRP, Calcitonin gene-related peptide; IL, Interleukin; MMP, Matrix
metalloproteinase; TIMP, Tissue inhibitor of metalloproteinase; TNF, Tumor
necrosis factor.
Wang et al. Arthritis Research & Therapy  (2015) 17:4 Page 4 of 12USA) overnight and then stored at −80°C for RNA extrac-
tion. (2) Some specimens were immersed in 4% para-
formaldehyde for 24 hours, washed, dehydrated with a
graded series of alcohol solutions and finally embedded in
paraffin for immunohistochemical (IHC) analysis. (3) The
rest of the sections were immediately stored at −80°C for
Western blot analysis.
Detection and analysis of substance P and CGRP in hip
joint synovial tissue by immunohistochemistry
Hematoxylin and eosin (H-E) (Sigma-Aldrich, St Louis,
MO, USA) staining and IHC staining for SP and CGRP
were performed. After citrate antigen retrieval and per-
oxidase inactivation, the synovial slides in each group
were incubated overnight with the primary antibodies to
SP (1:1,000 dilution, catalog number ab14184; Abcam,
Cambridge, UK) and CGRP (1:3,000 dilution, catalog
number ab36001; Abcam). After that, slides were incu-
bated with biotinylated secondary antibody (EnVision
system; Dako, Glostrup, Denmark) for 30 minutes.
Finally, 3′-diaminobenzidine tetrachloride was used for
visualization of immunoreactions. From every synovium
sample (six per group), two sections were acquired at dif-
ferent depths, and eight microscopic fields from each sec-
tion were photographed and analyzed. Immunoreactivity
was measured as the area in square millimeters using
Image-Pro Plus version 6.0 software (Media Cybernetics,
Rockville, MD, USA). The results are expressed in the
form of mean optical density, which we calculated as the
integral optical density value of each microscopic field in
relation to the actual synovial area.
Gene expression detection of substance P and CGRP in
synovium of hip joint by real-time PCR
Synovial tissues from fossa acetabuli were obtained dur-
ing THA or PAO, as described above, from 10 patientswith moderate DDH, 11 with severe DDH and 8 in the
control group. The sequences of primers used to amplify
mRNA are shown in Table 2. Real-time PCR was carried
out by using 200 ng of cDNA and the PrimeScript RT-PCR
Kit (catalog number DRR064A; Takara, Ōtsu, Japan) in 96-
well plates in an ABI 7500 Sequence Detection System
(Applied Biosystems, Foster City, CA, USA) according to
the manufacturer’s instructions. Relative quantification of
each gene was normalized to the housekeeping gene β-
actin. Relative mRNA expression levels of neuropeptides
were calculated by using the cycle threshold method [33].
Analysis of the results is based on at least three individual
experiments.
Enzyme-linked immunosorbent assay of neuropeptides
and cytokines in synovial fluid
Concentrations of TNF-α, IL-1β and IL-10 in SF were
detected by using human enzyme-linked immunosorbent
assay (ELISA) kits (catalog numbers EHC103a, EHC002b
and EHC009 (H), respectively; Xinbo Sheng, Shenzhen,
China) in accordance with the protocol provided by the
manufacturer. Levels of SP and CGRP in SF were mea-
sured with human ELISA kits (catalog numbers 589101
and 583751, respectively; Cayman Chemical, Ann Arbor,
MI, USA) according to the manufacturer’s instructions.
Incubation of human fibroblast-like synoviocytes
Fibroblast-like synoviocytes (FLSs) were isolated from
the hip joint synovium of patients with moderate DDH
during their PAO and OCP procedures. Synovial samples
were sheared into pieces 1 × 1 mm3 in size and repeatedly
washed with phosphate-buffered saline (PBS) and then
digested with collagenase I (1 mg/ml; Sigma-Aldrich) and
0.25% trypsin-ethylenediaminetetraacetic acid (catalog
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Island, NY, USA) for 3 hours and 1 hour, respectively, at
37°C. The cell suspension was filtered through a cell
strainer (80 mm) and washed with PBS. After centrifuga-
tion, cells were washed and seeded in Dulbecco’s modified
eagle medium/F-12 medium with 10% fetal calf serum
(FCS), 100 μg/ml penicillin and 100 U/ml streptomycin at
37°C, 95% air humidity and 5% CO2. Nonadherent cells
were discarded after overnight incubation. Cells were
plated at a density of 4 × 105 cells/dish in a six-well plate.
Cells at the third to sixth passages, which were recognized
as mature human synoviocytes (>95% FLS purity), were
prepared for further treatment [34,35].
Gene expression of inflammatory cytokines in cultured
fibroblast-like synoviocytes after treatment with substance
P or CGRP
We did a concentration gradient study by ELISA to obtain
the most suitable neuropeptide concentration according to
the production of inflammatory cytokines (IL-1β, TNF-α).
After 24-hour serum starvation (2% FCS), the neuropep-
tides SP (catalog number S6883; Sigma-Aldrich) and CGRP
(catalog number C0167; Sigma-Aldrich) were applied for
24 and 48 hours, respectively, as a time course study.
The relative expression of genes related to inflammation
and cartilage degeneration, including IL-1β, TNF-α, IL-6,
MMP-13, MMP-3 and tissue inhibitor of metalloprotein-
ase (TIMP)-1, was detected by using a real-time PCR
detection system. The results were normalized against β-
actin and control conditions. Three replicates were per-
formed, and the results were averaged.
Western blot analysis
Nuclear cell extracts were collected with a kit manufac-
tured by Active Motif (Carlsbad, CA, USA). Nucleus
protein lysates (30 μg) were separated by using 10% SDS-
PAGE gel and transferred onto a nitrocellulose membrane.
The membrane was blocked with 5% fat-free dry milk and
then incubated overnight at 4°C with a 1:1,000 dilution of
an anti-human phosphorylated and nonphosphorylated p65
antibody (catalog number 4767; Cell Signaling Technology,
Danvers, MA, USA). After being washed, the membrane
was incubated with a 1:1,000 dilution of a peroxidase-
conjugated anti-rabbit secondary antibody (catalog number
7074; Cell Signaling Technology) at room temperature for
2 hours. Detection was achieved with the help of an en-
hanced chemiluminescence kit (EMD Millipore, Billerica,
MA, USA). The Western blotting signals were measured by
scanning densitometry and normalized against β-actin
(catalog number 4967; Cell Signaling Technology).
NF-κB activation assay
The activation of NF-κB binding to DNA was measured
in nuclear extracts from synoviocytes pretreated with SP,CGRP and their inhibitors L-703606 (Sigma-Aldrich)
and MK-3207 (Selleck Chemicals, Houston, TX, USA) with
an ELISA-based TransAM NF-κB p65 assay kit (Active
Motif). The NF-κB complex binding to the oligonucleotide
was detected by spectrophotometry with the use of a
secondary antibody conjugated to horseradish peroxidase.
The results are presented as activation fold changes with
the unstimulated control set to 100%.
Enzyme-linked immunosorbent assay for role of NF-κB in
proinflammatory effect of substance P and CGRP on
synovial cells
Western blot analysis and NF-κB DNA binding assays
were carried out to select the effective concentration of
NF-κB inhibitor Bay 11–7085 (Sigma-Aldrich), which was
preincubated with synovial cells at 1 μM, 10 μM or 30 μM
for 2 hours, followed by treatment with SP (100 nM) or
CGRP (1 nM). To evaluate the contribution of NF-κB in
the secretion of cytokines, the synovial cells were preincu-
bated with L-703606 (10 μM), MK-3207 (1 μM) or Bay
11–7085 (30 μM) for 2 hours, followed by stimulation
with SP (100 nM) or CGRP (1 nM) for 24 hours. Superna-
tants were collected and prepared for analysis in which we
used ELISA kits specific for IL-1β and TNF-α.
Criteria for exclusion
Patients recruited into this study had no secondary
OA as a consequence of rheumatism, trauma, gout or
tumor. Patients with DDH secondary to slipped capital
femoral epiphysis or traumatic OA, as well as those who
underwent orthopedic surgery in the hip, were also
excluded.
Statistics
The results are expressed as mean ± standard deviation.
Statistical analyses were performed using SPSS statistical
software (SPSS, Chicago, IL, USA). Comparisons of SP
and CGRP levels in the synovium and SF in these groups
were carried out by using ELISA, immunohistochemistry
and real-time PCR; Student’s Mann–Whitney U test, a
two-tailed t-test and analysis of variance; and GraphPad
Prism version 5.01 software (GraphPad Software, La Jolla,
USA). P-values <0.05 were considered significant. After
adjustment for confounding factors, correlation analyses
were performed with Spearman’s rank correlation test.
A two-sided P-value <0.05 was considered statistically
significant.
Results
Increased vascularization and neuropeptide expression in
synovium and synovial fluid of patients with developmental
dysplasia of hip
During the progression from moderate to severe DDH,
the hip joint synovium showed much more extensive
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were detected by H-E staining (Figure 2A-C). IHC
staining (Figure 2D-I) and gray staining (Figure 2 J,K)
analyses showed stronger staining of SP and CGRP in
patients with severe DDH than in those with moderate
DDH and those in the control group. Analogous results
were also observed in the comparison of neuropeptide
gene expression in the synovial tissues of these groups
(Figure 1C,D). Furthermore, levels of SP and CGRP in
the SF of patients with severe DDH increased signifi-
cantly compared to levels in patients with moderate
DDH (Figure 1E,F). Additionally, in comparisons be-
tween the moderate and severe DDH groups regarding
inflammatory cytokines in SF, we found statistically
significant differences for IL-1β (P < 0.05) and TNF-α
(P < 0.05) (Figure 1G,H).Figure 2 Photomicrographs showing staining of substance P and calc
different groups. (A) Hematoxylin and eosin (HE) stain from the control s
capillaries in synovial tissues (HE staining). Red arrows in (D) through (I) ind
(D), (E) and (F)) or calcitonin gene-related peptide (CGRP; (G), (H) and (I)).
values of the positive immunohistochemical staining of SP and CGRP separ
*P < 0.05 versus control. #P < 0.05 versus moderate developmental dysplasiCorrelations between neuropeptides and cytokines in
synovial fluid
The results shown in Table 3 indicate that, in moderate
DDH cases, the concentration of SP in SF correlated with
TNF-α (rS = 0.41, P < 0.05) and CGRP in SF correlated
with IL-10 (rS = 0.69, P < 0.01) and TNF-α (rS = 0.40, P <
0.05). In severe DDH cases, the concentration of SP in SF
correlated with IL-1β (rS = 0.45, P < 0.05) and TNF-α (rS =
0.48, P < 0.05) and IL-10 (rS = 0.39, P < 0.05). Levels of
CGRP in SF correlated with TNF-α (rS = 0.47, P < 0.01).
Increased gene expression of inflammatory cytokines in
substance P- and CGRP-treated human synovial cells
The results of the concentration gradient study showed
that 100 nM SP and 1 nM CGRP had the strongest
proinflammatory effect (Figure 3A-D). After 24-houritonin gene-related peptide from synovial tissues among
ample. Blue arrows in (B) and (C) represent vessels or hyperplastic
icate positive immunohistochemical staining of substance P (SP;
Scale bars = 100 μm. (J) and (K) Graphs depict mean optical density
ately in each group. Data presented are mean ± standard deviation.
a of the hip (DDH).
Table 3 Correlation of substance P and CGRP with IL-1β, TNF-α and IL-10 in synovial fluid of patients with
developmental dysplasia of the hipa
Correlation of SF neuropeptide levels
Group Neuropeptide With IL-1β With TNF-α With IL-10
Moderate DDH R P-value R P-value R P-value
SP 0.19 0.30 0.41 <0.05* 0.33 0.08
CGRP 0.10 0.64 0.40 <0.05* 0.69 <0.01*
Severe DDH
SP 0.45 <0.05* 0.48 <0.05* 0.39 <0.05*
CGRP 0.37 0.07 0.47 <0.01* 0.14 0.46
aCGRP, Calcitonin gene-related peptide; DDH, Developmental dysplasia of the hip; IL, Interleukin; R, Correlation index; SF, Synovial fluid; SP, Substance P; TNF,
Tumor necrosis factor. *A two-sided P-value <0.05 indicates a significant correlation with the corresponding neuropeptide in each column.
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cytokines (IL-1β, TNF-α) and collagen metabolism-related
factors (TIMP-1 and MMP-13) were observed in synovio-
cytes with SP compared to the unstimulated group. The
trend weakened with time. In addition, CGRP could up-
regulate the expression of these cytokines by 2 days of
culture, which might indicate a delayed inflammatory
effect (Figure 3E-J).
Effects of substance P and CGRP in activation of NF-κB
pathway in synovial cells
As shown in Figure 4A and 4B, SP could stimulate the
activation of phosphorylated p65 (phospho-p65) in syn-
ovial cells. The activation was evident at 30 minutes and
increased up to 45 minutes. Analogously, as shown in
Figure 4C and 4D, CGRP could also induce an increase
of phospho-p65 at 45 minutes compared to control.
NF-κB p65 DNA binding assays in (Figure 4E,F) re-
vealed that treatment with either SP or CGRP could lead
to a notable increase in the activity of NF-κB p65 and that
this effect could be blocked by the inhibitors of these neu-
ropeptides (L-703606 for SP and MK-3207 for CGRP).
Effect of NF-κB inhibitors on secretion of inflammatory
cytokines in synovial cells
Western blot and NF-κB DNA binding assays (Figure 5A-
D) showed that Bay 11–7085 (30 μM) could effectively
block the activation of the NF-κB pathway. Treatment of
synoviocytes with 100 nM SP or 1 nM CGRP led to obvi-
ous upregulated secretion of IL-1β and TNF-α compared
to unstimulated cells. Bay 11–7085 (30 μM) could signifi-
cantly block the proinflammatory effect of SP on synovio-
cytes (Figure 5E,F), but the proinflammatory effect of
CGRP could not be inhibited in the presence of Bay
11–7085 (Figure 5G,H).
Discussion
Because our department is the largest DDH center in
China (with more than 300 young patients diagnosed with
DDH every year), it provides convenience for acquiringprecious synovial tissues and fluid samples during surgery.
This is the first time that the histological characteristics of
synovial tissue were obtained from a diverse sample of pa-
tients with moderate or severe DDH. We are probably the
pioneers in incubating synoviocytes from patients with
moderate DDH in in vitro experiments and the first to in-
vestigate the proinflammatory effects of SP and CGRP on
synoviocytes. In addition, for the first time, upregulated
expression of neuropeptides in the hypertrophic synovial
tissue of patients with DDH was detected by IHC staining.
We know that pain signal neuropeptides (SP and CGRP)
are synthesized mainly in sympathetic ganglia and trans-
ferred and secreted by peripheral sympathetic fibers. Our
observations in this study suggest that more sympathetic
fibers might migrate and distribute into the hip joint with
the development of DDH. These nerve fibers might also
engage in the transmission of pain sensation in the hip
joint, which helps us better understand the mechanisms
of pain creation and the progression of inflammation in
different stages of DDH.
In this study, we divided patients with DDH into two
groups (moderate DDH and severe DDH). By doing so,
we aimed to investigate the differences in pathophysio-
logical processes and inflammatory conditions between
these groups and to identify the role of SP and CGRP in
the progression from moderate to severe DDH. The re-
sults of immunohistochemistry, real-time PCR and ELISA
experiments demonstrated remarkable upregulation of SP
and CGRP in both synovium and SF obtained from
patients with severe DDH compared with those from pa-
tients with moderate DDH. Previous studies demonstrated
that, with the stimulation of peripheral pain, SP and CGRP
were increasingly synthesized in dorsal root ganglia
(DRG), then secreted by peripheral sensory nerve endings
[36]. On the basis of our findings, we speculate that, with
the time and duration of DDH, the degree of cartilage
wearing gradually increases and the cushioning capacity of
cartilage progressively disappears. If that is true, the
subchondral bone and labrum tissue will bear increasing
shear and compressive loading as cartilage destruction
Figure 3 The proinflammatory effect of neuropeptides on synoviocytes in vitro. (A-D) Dose dependence of substance P (SP)- and
calcitonin gene-related peptide (CGRP)-induced tumor necrosis factor (TNF)-α and interleukin (IL)-1β production. *P < 0.05 and **P < 0.01 versus
control. (E-J) Genes for inflammation-related cytokines and cartilage erosion factors were evaluated in cultured fibroblast-like synoviocytes after
24 or 48 hours of treatment with SP or CGRP, respectively. MMP, Matrix metalloproteinase; TIMP, Tissue inhibitor of metalloproteinase. The error
bars indicate the standard deviation. *P < 0.05. Three replicates were performed, and the results were averaged.
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pain is gradually increased, which can in turn induce
greater infiltration of peripheral nerve fibers with in-
creased release of neuropeptides from DRG. In this way,
the progression and duration of DDH might stimulate
the release of SP and CGRP from nerve fibers in syn-
ovial tissue.
In the IHC staining and ELISA experiments, we de-
tected increasing CGRP levels in both synovium and SFwith the progression of DDH. We also observed signifi-
cant proinflammatory capacities of CGRP by real-time
PCR (Figure 4) and correlation between CGRP and cyto-
kines (IL-1β, TNF-α and IL-10) in the SF of patients with
moderate or severe DDH (Table 3). A previous study
proved that CGRP neurons play crucial roles in the per-
ception of pain in the hip joint [37-39]. Collectively, our
results favor the hypothesis that CGRP might be involved
in not only the hyperalgesia but also the regulation of
Figure 4 Activation of NF-κB pathway evaluated by Western blot analysis and NF-κB DNA binding assay. (A-D) Synoviocytes obtained
from patients with developmental dysplasia of the hip (DDH) were incubated with 100 nM substance P (SP) or 1 nM calcitonin gene-related
peptide (CGRP) within 1 hour. Nuclei cell proteins were subjected to Western blot analysis (A) and (C) with antibodies against phosphorylated
p65 (p-P65). (B) and (D) Densitometric analysis of Western blotting data derived from (A) and (C). *P < 0.05 versus control. (E) and (F) Nuclear
factor κ-light-chain-enhancer of activated B cells (NF-κB) p65 and DNA binding assays. Synoviocytes were pretreated with L-703606 or MK-3207
for 2 hours, followed by 1 hour of stimulation with SP (100 nM) or CGRP (1 nM). *P < 0.05 versus control. #P < 0.05 versus synoviocytes stimulated
with SP or CGRP alone.
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DDH, which probably have an impact on the pathological
process of DDH.
Similarly, we also observed the upregulation of SP
levels in synovial tissues obtained from patients with
different stages of DDH compared with those obtained
from the control group. It has been reported that SP is
involved in the mediation of inflammatory hyperalgesia
and immune regulation [40]. In this study, we explored
the possible correlation between SP and inflammatory cy-
tokines in the SF of patients with severe DDH. We also in-
vestigated the proinflammatory effects of SP in real-time
PCR and ELISA experiments, which can be considered
direct evidence of SP’s involvement in inducing inflamma-
tory infiltration and the severity of DDH that develops.
In Western blot analysis and NF-κB DNA binding as-
says, we witnessed the obvious activation of phospho-
p65 protein after stimulation with SP or CGRP. The
activation of NF-κB, the principal transcriptional regula-
tor of inflammation, was previously demonstrated to be
upregulated in synovial and cartilage samples in severalanimal models of arthritis [41,42]. By the same token,
the proinflammatory effect of SP and CGRP associated
with the activation of NF-κB pathway has been proved
through the culture of synovial cells in vitro. Furthermore,
when blocked by the inhibitor of NF-κB, the inflammation-
promoting effect of SP on synovial cells was obviously re-
strained (Figure 5E,F). However, suppressing the role of
NF-κB in CGRP-pretreated synovial cells could not ef-
fectively diminish the release of inflammatory mediators
(Figure 5G,H). Thus, it appears that the activation of
NF-κB might not crucially mediate or be involved in the
release of inflammatory cytokines induced by CGRP.
Though previous studies proved that both SP and CGRP
have strong vasodilatation and inflammation chemotactic
abilities, there are also some theories that neuropeptides
may have diverse roles in the inflammatory process [43,44].
Yuko et al., for example, reported that CGRP could inhibit
the synoviocyte proliferation and cytokine-induced IL-6,
IL-8 and MMP-2 release of synoviocytes from patients
with RA [45]. However, in our study, we observed proin-
flammatory effects of CGRP on synoviocytes from patients
Figure 5 The role of the NF-κB pathway played in the proinflammatory effect of substance P and calcitonin gene-related peptide on
synovial cells. (A-D) Western blot and DNA binding assays were carried out for the selection of effective concentration of Bay 11–7085. CGRP,
Calcitonin gene-related peptide; NF-κB, Nuclear factor κ-light-chain-enhancer of activated B cells; p-P65, Phosphorylated p65; SP, Substance P.
(E-H) Supernatants were collected from each group and prepared for enzyme-linked immunosorbent assay kits specific for interleukin (IL)-1β and
tumor necrosis factor (TNF)-α. Mean production (in picograms per milliliter (pg/ml)) of IL-1β and TNF-α in unstimulated synovial cells was used as
a control (100% production). IL-1β and TNF-α production (pg/ml) by the other incubation cultures are expressed as the percentage of control.
*P < 0.05 versus control. #P < 0.05 versus stimulation with SP or CGRP alone. Three replicates were performed, and the results were averaged. Data
are represented as mean ± standard deviation.
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relates to synoviocytes between patients with RA and pa-
tients with DDH is not clear. In addition to the different
inflammation sources, which could affect the functional re-
action of these two cells, the diverse treatment time and
the environment could explain the discrepancy in the in-
flammatory capabilities of the same neuropeptide in the
different settings.
Our study has some limitations. First, owing to med-
ical ethical requirements, it is impossible to obtain per-
fectly normal synovial specimens. Referring to previousstudies on hip joint disease [28-30], we chose patients
with femoral head or neck fracture as a control group.
Second, as we conducted a kind of phenomenal observa-
tional research, the number of patients recruited into each
group was not great enough to draw firm conclusions
from our results; more tissue samples would have been
needed. Additionally, the synoviocytes cultured in vitro
were obtained from the synovium of patients with moder-
ate DDH, but not from patients with severe DDH. We
dedicated our study to exploring novel nonoperative mea-
sures to prevent arthritis progression in the primary stage
Wang et al. Arthritis Research & Therapy  (2015) 17:4 Page 11 of 12of DDH (moderate DDH), which probably makes more
sense than that preventing it in the late stage of DDH
(severe DDH). Thus, our results are more targeted on the
pathological characteristics of synovium from patients
with moderate DDH.
Conclusions
In general, we observed that SP and CGRP might be in-
volved in the initiation and progression of inflammation
in patients with DDH. These findings may help to pro-
vide clinical guidelines for novel treatment of patients
with DDH. For example, synovectomy, nerve block sur-
gery and intra-articular injection of neuropeptide pathway
blockers could be meaningful measures to relieve pain
sensation and to slow down the progression of arthritis in
patients with DDH.
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